Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab

2 Aug 2021

Abstract excerpt

Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is highly variable, suggesting that a fixed dosage and time scheduling might be not optimal. We aimed to investigate whether B cell repopulation kinetics influences clinical and radiological outcomes and whether circulating immune asset at baseline affects B cell repopulation kinetics. Methods: 218 MS patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Multiple Sclerosis Research Studies
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34360456
DOI: 10.3390/ijerph18158163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with OcrelizumabPMID 34360456Read ↗

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read ↗

B cell-extrinsic and intrinsic factors linked to early immune repletion after anti-CD20 therapy in patients with Multiple Sclerosis of African AncestrySemantic proximity Read ↗

B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple SclerosisSemantic proximity Read ↗

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read ↗

Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.Semantic proximity Read ↗

Fingolimod alters intrathecal B cell maturation in multiple sclerosis patientsSemantic proximity Read ↗

Oligoclonal Immunoglobulin Gamma Bands and Long-Term Disability Progression in Multiple Sclerosis: A Retrospective Cohort StudySemantic proximity Read ↗

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.Semantic proximity Read ↗

IFNβ-1b treatment leads to changes in the B cell subset and cytokine secretion profile in patients with relapsing-remitting multiple sclerosisSemantic proximity Read ↗

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.